



Global Cancer Therapeutics Market: *Emphasis on Recurrent and Metastatic Divisions*

December 2017

Paul Taylor

Report Code: PHM177A

Table of Contents

Chapter 1: Introduction	1
Study Goals and Objectives.....	2
Scope of Report.....	2
Methodology and Information Sources	3
Primary Data and Information Gathering	3
Secondary Data and Information Gathering	3
Market Share Analysis and Market Forecast Prediction	4
Geographic Breakdown.....	4
Analyst's Credentials.....	7
Related BCC Research Reports.....	8
Chapter 2: Summary and Highlights	10
Chapter 3: Incidence, Prevalence and Mortality Statistics for Cancer: A Global Summary	13
Cancer: The Disease	13
Cancer: A Statistical Analysis of the Disease Incidence and Prevalence.....	14
Incidence and Prevalence Rates for Major Cancer Types	14
Regional Patterns of Cancer.....	23
Europe	23
North America	23
Asia-Pacific.....	25
Latin and Central America	26
Middle East/Africa.....	26
The Global Cancer Burden and Worldwide Cancer Risk Factors	27
Tobacco Use and Statistics	27
Alcohol Abuse and Cancer Statistics	28
Obesity and Cancer Statistics	28
Infectious Diseases and Cancer	28
Inherited Genes/Diseases and Cancer	29
Sun, Ultraviolet Radiation and Cancer	30
Hormones and Cancer	30
Chapter 4: Metastasis and Current Understanding of the Mechanisms of Resistance and Recurrence in Metastatic Cancer	32
What is Metastatic Cancer	32
Pathophysiology.....	32
Routes of Metastasis.....	34
Diagnosis	35
Classification of Metastasis.....	36
Metastasis: Common Sites of Origin.....	38
The Lung	38
The Breast.....	38
Melanoma	41
The Colon.....	42
The Kidney.....	43
The Prostate	43

The Pancreas	45
The Liver	47
The Cervix	48
Essential Understanding in Cancer Biology.....	49
Current Understanding of Mechanisms of Resistance and Recurrence in Metastatic Cancer.....	49
Inherent Resistance.....	50
Acquired Resistance	50
Chapter 5: Cancer: Current Therapy Strategies	58
General Treatment Strategies.....	58
Cancer Drug Treatment Strategies.....	59
Surgery for Cancer	61
Radiotherapy for Cancer	63
Cytotoxic Cancer Chemotherapy	64
Cytotoxic Cancer Drugs Classification	65
Hormone-based Cancer Drugs.....	68
Targeted Biologic Therapy	70
Monoclonal Antibodies (MAB)	70
Cancer Growth Blockers.....	74
Blood Cell Growth Factors.....	85
Cancer Vaccines.....	86
Gene Therapy.....	87
Drugs that Block Cancer Blood Vessel Growth (Antiangiogenics)	89
Cytokines (Interferon and Interleukin 2)	89
Personalized Cancer Therapy (Precision Medicine).....	90
Chapter 6: Metastatic Cancer Treatment Options by Tumor Origin	93
Bladder	94
Surgery	95
Radiation Therapy	95
Chemotherapy.....	96
Immunotherapy.....	97
Breast	98
Hormone Therapy	99
Targeted Therapy	101
Chemotherapy and Radiology.....	102
Other Treatment Options.....	106
Surgery	107
Colorectal	107
Standard Treatment Options for Stage IV and Recurrent Rectal Cancer	108
Standard Treatment Options for Stage IV and Recurrent Colon Cancer.....	111
Kidney	112
Renal Cell Cancer (RCC) Treatment	112
Transitional Cell Cancer (TCC) of the Renal Pelvis and Ureter	114
Lung.....	115
Treatment Options for Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC)	116
Melanoma	122
Treatments for Stage IV Melanoma, Recurrent and Metastatic Melanoma	125
Ovary.....	128
Treatments for Stage IV Melanoma, Recurrent and Metastatic Melanoma	129
Pancreas.....	132

Prostate.....	135
Radiation Therapy	136
Hormone Therapy	136
Androgen Deprivation, an Adjuvant Therapy.....	138
Immunotherapy/Therapeutic Vaccines.....	140
Vascular-Targeted Photodynamic Therapy	141
Stomach	141
Surgery	143
Chemotherapy.....	144
Radiation Therapy	144
Chemoradiation Therapy.....	145
Targeted Therapy	145
Thyroid	146
Surgery	148
Radiation Therapy, Including Radioactive Iodine Therapy.....	148
External Beam Radiation Therapy for Thyroid Cancer	149
Targeted Therapy	149
Uterus.....	150
Stage I and Stage II Endometrial Cancer	151
Stage III, Stage IV, and Recurrent Endometrial Cancer	152
Chapter 7: Global Market for Cancer Therapeutics by Cancer Type	156
Global Cancer Therapeutics Market, by Cancer Type.....	156
Market Dynamics	159
Global Market Drivers	159
Global Market Restraints	164
Regional Cancer Drugs Market Assessment: North America	166
Selected Market Drivers: North America	168
Selected Market Restraints: North America	170
Selected Country: Cancer Drugs Market, by Cancer Type	171
Regional Cancer Drugs Market Assessment: Europe.....	173
Selected Market Drivers: Europe	176
Selected Market Restraints: Europe.....	177
Selected Country: Cancer Drugs Market, by Cancer Type	178
Regional Cancer Drugs Market Assessment: Asia-Pacific	185
Selected Market Drivers: Asia-Pacific.....	188
Selected Market Restraints: Asia-Pacific.....	189
Selected Country: Cancer Drugs Market, by Cancer Type	192
Regional Cancer Drugs Market Assessment: Central and Latin America.....	196
Selected Market Drivers: Central and Latin America	199
Selected Market Restraints: Central and Latin America	200
Selected Country: Cancer Drugs Market, by Cancer Type	202
Regional Cancer Drugs Market Assessment: Middle East/Africa	205
Selected Market Drivers: Middle East/Africa	207
Selected Market Restraints: Middle East/Africa	208
Selected Region: Cancer Drugs Market, by Cancer Type	209
Chapter 8: Regulatory and Legislative Requirements	212
The United States.....	212
Canada	214
Europe.....	215

Mutual Recognition Procedure (MRP)	216
Decentralized Procedure (DCP)	217
Centralized Procedure (CP)	217
Japan	219
Marketing Authorization System	219
Pharmaceutical Reimbursement Approval Process in Japan	220
China	222
Overview of the Healthcare System.....	222
Pharmaceutical Regulatory and Legislative Developments: China	223
India	226
Overview of the Healthcare System.....	226
National Level.....	226
State Level	226
Regional Level.....	227
District Level.....	227
Sub-Divisional/Taluka Level.....	227
Community Level.....	227
Primary Health Center's (PHC) Level	227
Sub Health Center (SHC) Level	227
Hospital Resources	229
Population Statistics	229
Pharmaceutical Regulatory and Legislative Developments: India	230
South Korea.....	231
Regulatory and Legislative Requirements.....	231
Pharmaceutical Regulatory and Legislative Developments: South Korea	232
Pharmaceutical Reimbursement: South Korea	232
Brazil.....	233
Market Entry and Reimbursement of Pharmaceuticals.....	234
Argentina.....	234
Background.....	234
Government-funded Public Health Sector	234
Social Health Insurance Sector	235
Private Sector	236
Regulatory and Legislative Requirements.....	236
Mexico.....	239
Regulation and Regulation Governing Medical Devices and Drugs in Mexico	239
Health Insurance Structure in Mexico.....	240
South Africa.....	240
Regulatory Requirements: South Africa.....	240
Health Insurance Structure: South Africa.....	241
Reimbursement of Pharmaceuticals: South Africa	242
Saudi Arabia	242
The Public Healthcare System	242
Primary Healthcare Services.....	243
Secondary and Tertiary Healthcare Services.....	243
The Private Healthcare Sector.....	244
Pharmaceutical Regulatory Requirements: Saudi Arabia	244
Health Insurance Structure: Saudi Arabia	245
Chapter 9: Patent Review/ New Developments	248
Filed Patents by Clinical Application	250

Filed Patents Cited for Metastatic Breast Cancer (01-01-2016 to 05-26-2017).....	250
Filed Patents Cited for Metastatic Prostate Cancer (11-05-2015 to 05-11-2017)	255
Filed Patents Cited for Metastatic Lung Cancer (11-05-2015 to 05-11-2017)	258
Filed Patents Cited for Other Cancer Types (11-05-2015 to 06-07-2017)	260
Filed Patents and Expiry Dates for Major Products by Leading Suppliers	262
Pfizer Inc.	262
Merck & Co.	264
Johnson & Johnson.....	264
F Hoffman La Roche	265
Sanofi S.A.	266
Novartis AG.....	268
Abbvie Inc.	271
AstraZeneca PLC.....	271
Gilead Sciences	272
Filed Patents and Expiry Dates for Other Products and Suppliers.....	273
Targeting Breakpoint Cluster Region-Abelson (BCR-ABL)	273
Targeting Epidermal Growth Factor Receptor (EGFR/ERBB1)	273
Targeting Vascular Endothelial Growth Factor Receptor (VEGFR), PDGFR and Ret Proto-Oncogene (RET)	274
Latest Approved Immunotherapy Drugs.....	274
Chapter 10: Company Profiles	277
The Top 10 Multinational Pharmaceutical Companies.....	277
Other Key Pharmaceutical Company Suppliers	306
Appendix: Company Contact Details	338
Company Addresses and Contact Details	338
Government Regulatory Agencies and Professional Organizations	351
Commonly Used Acronyms Associated with Metastatic and Recurrent Cancer	354
About BCC Research.....	362
About BCC Research.....	363
BCC Membership	363
BCC Custom Research	363

List of Tables

Summary Table: Global Cancer Therapeutics Market, by Cancer Type, Through 2022 (\$ Millions)	10
Table 1 Global Statistics: Estimated Incidence, Mortality and Five-Year Prevalence, 2012	15
Table 2 Global Statistics: Estimated Incidence, Mortality and Five-Year Prevalence (in Men and Women Combined), by Cancer Type, 2012	16
Table 3 Global Statistics: Estimated Incidence, Mortality and Five-Year Prevalence (Men), by Cancer Type, 2012.....	19
Table 4 Global Statistics: Estimated Incidence, Mortality and Five-Year Prevalence (Women), by Cancer Type, 2012.....	21
Table 5 Estimated Number of New Cancer Cases by Sex: The United States, 2017 (NO./%)	24
Table 6 Estimated Number of Deaths from Cancer by Sex: The United States, 2017 (NO./%)	25
Table 7 Common Sites for Metastasis.....	41
Table 8 Cancer Treatment Options.....	58
Table 9 Cancer Drug Treatment Classification	59
Table 10 Advantages of Minimally Invasive Surgery.....	61
Table 11 FDA Approved Therapeutic Monoclonal Antibodies used to Treat Cancer, 1997-2017	73
Table 12 Approved Tyrosine kinase inhibitors (TKIs) used to Treat Cancer	82
Table 13 Common Sites for Metastasis.....	94
Table 14 Common Chemotherapeutic Agents for Recurrent and Metastatic Breast Cancer.....	103
Table 15 Chemotherapeutic Combinations for Recurrent and Metastatic Breast Cancer	106
Table 16 Treatment Options for Stage IV and Recurrent Colon Cancer	111
Table 17 Drugs Approved for the Treatment of Lung Cancer.....	119
Table 18 Drugs Approved for the Treatment of Melanoma	124
Table 19 Drugs Approved for Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	130
Table 20 Combination Drugs Approved for Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.....	132
Table 21 Drugs Approved for Pancreatic Cancer	134
Table 22 Drugs Approved for Pancreatic Cancer	134
Table 23 Hormone Therapy for Prostate Cancer	137
Table 24 Drugs Approved for Prostate Cancer	139
Table 25 Drugs Approved for Stomach (Gastric) Cancer	145
Table 26 Drugs Combinations Approved for Stomach (Gastric) Cancer	146
Table 27 Drugs Approved for Gastroenteropancreatic Neuroendocrine Tumors	146
Table 28 Treatment Option Overview for Thyroid Cancer	147
Table 29 Drugs Approved for Thyroid Cancer.....	149
Table 30 Treatment Option Overview for Endometrial Cancer	151
Table 31 Global Cancer Therapeutics Market, Through 2022 (\$ Millions)	156
Table 32 Global Cancer Therapeutics Market, by Cancer Type, Through 2022 (\$ Millions).....	157
Table 33 Global Cancer Therapeutics Market and Market Share, by Cancer Type, 2017 (\$ Millions/%)	158
Table 34 North American Cancer Therapeutics Market, Through 2022 (\$ Millions).....	166
Table 35 North American Therapeutics Market, by Cancer Type, Through 2022 (\$ Millions)	167
Table 36 North American Market Share, by Individual Country, 2017 (\$ Millions/%)	168
Table 37 United States' Therapeutics Market, by Cancer Type, Through 2022 (\$ Millions)	171
Table 38 Canadian Therapeutics Market, by Cancer Type, Through 2022 (\$ Millions)	173
Table 39 European Cancer Therapeutics Market, Through 2022 (\$ Millions)	174
Table 40 European Therapeutics Market, by Cancer Type, Through 2022 (\$ Millions)	174
Table 41 European Market Share, by Individual Country, 2017 (\$ Millions/%).....	175
Table 42 France's Therapeutics Market, by Cancer Type, Through 2022 (\$ Millions).....	179
Table 43 Germany's Therapeutics Market, by Cancer Type, Through 2022 (\$ Millions).....	180

Table 44	Italy's Therapeutics Market, by Cancer Type, Through 2022 (\$ Millions)	181
Table 45	Spain's Therapeutics Market, by Cancer Type, Through 2022 (\$ Millions)	182
Table 46	United Kingdom's Therapeutics Market, by Cancer Type, Through 2022 (\$ Millions)	182
Table 47	Benelux's Therapeutics Market, by Cancer Type, Through 2022 (\$ Millions)	183
Table 48	Scandinavia's Therapeutics Market, by Cancer Type, Through 2022 (\$ Millions)	184
Table 49	Rest of Europe's Therapeutics Market, by Cancer Type, Through 2022 (\$ Millions)	184
Table 50	Asia-Pacific Cancer Therapeutics Market, Through 2022 (\$ Millions)	185
Table 51	Asia-Pacific Therapeutics Market, by Cancer Type, Through 2022 (\$ Millions)	186
Table 52	Asia-Pacific Market Share, by Individual Country, 2017 (%)	187
Table 53	Japanese Therapeutics Market, by Cancer Type, Through 2022 (\$ Millions)	192
Table 54	Chinese Therapeutics Market, by Cancer Type, Through 2022 (\$ Millions)	193
Table 55	Indian Therapeutics Market, by Cancer Type, Through 2022 (\$ Millions)	193
Table 56	South Korean Therapeutics Market, by Cancer Type, Through 2022 (\$ Millions)	194
Table 57	Taiwan's Therapeutics Market, by Cancer Type, Through 2022 (\$ Millions)	195
Table 58	Rest of Asia-Pacific Therapeutics Market, by Cancer Type, Through 2022 (\$ Millions)	195
Table 59	Central and Latin American Cancer Therapeutics Market, Through 2022 (\$ Millions)	196
Table 60	Central and Latin American Therapeutics Market, by Cancer Type, Through 2022 (\$ Millions)	197
Table 61	Central and Latin American Market Share, by Individual Country, 2017 (\$ Millions/%)	198
Table 62	Argentina's Therapeutics Market, by Cancer Type, Through 2022 (\$ Millions)	202
Table 63	Brazil's Therapeutics Market, by Cancer Type, Through 2022 (\$ Millions)	203
Table 64	Chile's Therapeutics Market, by Cancer Type, Through 2022 (\$ Millions)	203
Table 65	Mexico's Therapeutics Market, by Cancer Type, Through 2022 (\$ Millions)	204
Table 66	Rest of Central and Latin America's Therapeutics Market, by Cancer Type, Through 2022 (\$ Millions)	205
Table 67	Middle East/Africa's Cancer Therapeutics Market, Through 2022 (\$ Millions)	206
Table 68	Middle East/Africa's Therapeutics Market, by Cancer Type, Through 2022 (\$ Millions)	206
Table 69	Middle East/Africa's Market Share, by Individual Country, 2017 (\$ Millions/%)	207
Table 70	Middle East's Therapeutics Market, by Cancer Type, Through 2022 (\$ Millions)	209
Table 71	Africa's Therapeutics Market, by Cancer Type, Through 2022 (\$ Millions)	210
Table 72	Overview of Healthcare in India	228
Table 73	Latest Patent Publications Cited Relating to Metastatic Breast Cancer, 2016-May 2017	251
Table 74	Latest Patent Publications Cited Relating to Metastatic Prostate Cancer, 2015-May 2017	255
Table 75	Latest Patent Publications Cited Relating to Metastatic Lung Cancer, 2015-March 2017	258
Table 76	Latest Patent Publications Cited Relating to Other Metastatic Cancers, 2015-March 2017	260
Table 77	Pfizer Inc. Patent Expiry Dates for Leading Cancer Drugs	263
Table 78	Merck & Co Patent Status Leading Oncology Products	264
Table 79	Johnson & Johnson Patent Status Leading Oncology Products	265
Table 80	F Hoffman La Roche Patent Status Leading Oncology Products	266
Table 81	Sanofi S.A. Patent Status Leading Oncology Products	267
Table 82	AstraZeneca plc Patent Status Leading Oncology Products	272
Table 83	Top 10 Pharmaceutical Companies 2017 (\$ Millions/%)	277
Table 84	Abbvie Inc. Company Financials, by Product, 2014-2016 (\$ Millions)	279
Table 85	Amgen Company Financials, 2014-2016 (\$ Millions)	282
Table 86	Amgen Company Financials, by Product, 2014-2016 (\$ Millions)	283
Table 87	AstraZeneca plc Company Financials, by Therapeutic Product Group, 2014-2016 (\$ Millions)	285
Table 88	AstraZeneca plc Company Financials, by Oncology Product Group, 2014-2016 (\$ Millions)	285
Table 89	Gilead Sciences Summary Financials, 2014-2016 (\$ Millions)	286
Table 90	Gilead Sciences Product Pipeline	286
Table 91	F Hoffman La Roche Summary Financials, 2014-2016 (\$ Millions)	289

Table 92 F Hoffman La Roche Pharmaceutical Division Financials, 2014-2016 (\$ Millions).....	289
Table 93 F Hoffman La Roche Pharmaceutical Division Oncology Product Sales, 2014-2016 (\$ Millions)	290
Table 94 Johnson & Johnson Summary Financials, 2014-2016 (\$ Millions)	292
Table 95 Johnson & Johnson Pharmaceutical Therapeutic Area Product Sales, 2014-2016 (\$ Millions)	293
Table 96 Johnson & Johnson Oncology Product Sales, 2014-2016 (\$ Millions).....	294
Table 97 Merck & Co Inc. Therapeutic Area Product Sales, 2014-2016 (\$ Millions)	295
Table 98 Merck & Co Oncology Product Sales, 2014-2016 (\$ Millions).....	296
Table 99 Novartis AG Summary Financials, 2014-2016 (\$ Millions)	297
Table 100 Novartis AG Summary Financials, 2014-2016 (\$ Millions)	298
Table 101 Novartis AG Major Development Projects	299
Table 102 Pfizer, Inc. Summary Financials, 2014-2016 (\$ Millions).....	301
Table 103 Pfizer, Inc. Innovative Health (IH) Division Financials, 2014-2016 (\$ Millions)	302
Table 104 Pfizer, Inc. Innovative Health (IH) Division Oncology Product Sales, 2014-2016 (\$ Millions).	303
Table 105 Sanofi S.A. Summary Financials, 2014-2016 (\$ Millions)	304
Table 106 Sanofi S.A. Oncology Product Sales, 2014-2016 (\$ Millions).....	306
Table 107 Array Biopharma Inc. Clinical Stage Drug Portfolio.....	307
Table 108 Astellas Pharma Inc Innovative Health (IH) Division Oncology Product Sales, 2014-2016 (\$ Millions)	309
Table 109 Bayer AG Company Financials, 2014-2016 (\$ Millions).....	310
Table 110 Bayer AG Oncology Product Sales, 2014-2016 (\$ Millions).....	311
Table 111 Biogen, Inc. Summary Company Financials, 2014-2016 (\$ Millions).....	312
Table 112 Bristol-Myers Squibb Segment Product Sales, 2014-2016 (\$ Millions).....	313
Table 113 Bristol-Myers Squibb Oncology Product Sales, 2014-2016 (\$ Millions)	314
Table 114 Celgene Corporation Financial Summary, 2014-2016 (\$ Millions).....	316
Table 115 Eisai Co., Ltd. Financial Summary, 2014-2016 (\$ Millions).....	319
Table 116 Eisai Co., Ltd Oncology Product Sales, 2014-2016 (\$ Millions)	319
Table 117 Eli Lilly and Company Selected Product Sales, 2014-2016 (\$ Millions)	321
Table 118 GlaxoSmithKline Financial Summary by Segment, 2014-2016 (\$ Millions).....	323
Table 119 GlaxoSmithKline Pharmaceuticals Turnover by Therapeutic Area, 2014-2016 (\$ Millions) ...	324
Table 120 GlaxoSmithKline Oncology Product Pipeline.....	324
Table 121 Incyte Corporation Company Revenues, 2014-2016 (\$ Millions)	328
Table 122 Tekada Company Revenues, 2014-2016 (\$ Millions)	332
Table 123 Regeneron Pharmaceuticals, Inc. Company Revenues, 2014-2016 (\$ Millions)	334
Table 124 Company Addresses and Contact Details.....	338
Table 125 Government Regulatory Agencies and Professional Organizations associated with Metastatic and Recurrent Cancer	351
Table 126 Commonly Used Acronyms Associated with Metastatic and Recurrent Cancer	354

List of Figures

Summary Figure Global Cancer Therapeutics Market Share, by Cancer Type, 2017 (%)	11
Figure 1 Estimated World Cancer Incidence Proportions, by Cancer type, in Men and Women Combined, 2012 (Cases/%)	18
Figure 2 Estimated World Cancer Incidence Proportions, by Cancer Type, in Men, 2012 (Cases/%)	20
Figure 3 Estimated World Cancer Incidence Proportions, by Cancer Type, in Women, 2012 (Cases/%)..	22
Figure 4 Metastatic Sites for Common Cancers.....	40
Figure 5 Schematic of Acquired Resistance Mechanisms.....	51
Figure 6 The Intrinsic and Extrinsic Pathways of Apoptosis.....	53
Figure 7 Managing Locally Advanced or Metastatic Bladder Cancer.....	96
Figure 8 Global Market Share, by Cancer Type, 2017 (%).....	159
Figure 9 All Cancers, Average Number of New Cases per Year and Age-Specific Incidence Rates, U.K. 2012-2014 (No. of Cases).....	160
Figure 10 North American Market Share, by Individual Country, 2017 (%)	167
Figure 11 Estimates and Projections of Metastatic Breast Cancer (MBC) Prevalence in the United States, 1990-2020	169
Figure 12 European Market Share, by Individual Country, 2017 (%).....	175
Figure 13 Asia-Pacific's Market Share, by Individual Country, 2017 (%)	187
Figure 14 Central and Latin American Market Share, by Individual Country, 2017 (%)	198
Figure 15 Middle East/Africa's Market Share, by Individual Country, 2017 (%).....	207
Figure 16 Drug Discovery and Development Time Line.....	213
Figure 17 Mutual Recognition Procedure	216
Figure 18 Decentralized Procedure.....	218
Figure 19 Japan's Drug Funding/Reimbursement Approval Procedure	221
Figure 20 The Chinese Healthcare System.....	222
Figure 21 Argentina: Regulatory Drug Approval Procedure Standard Review 120-240 Business Days* for Approval**	238
Figure 22 Current Structure of the Health Care Sectors in Saudi Arabia.....	245



About BCC Research

About BCC Research

With our unparalleled 45-year history, BCC Research provides comprehensive analysis of global market sizing, forecasting and industry intelligence, covering markets where advances in science and technology are improving the quality, standard and sustainability of businesses, economies and lives.

BCC Membership

From market sizing and forecasts, to opportunity assessments and competitive analyses, our ever-expanding library gives you the data, insights and intelligence required to ensure your project is a success. Members benefit from ongoing, unlimited access to the category or collections of their choice, and most membership packages pay for themselves within two to three reports being accessed.

Did you buy this report? You may qualify to apply your purchase price towards a full membership. Call 866/285-7215 or e-mail info@bccresearch.com to request a demo.

BCC Custom Research

Our experts provide custom research projects to those working to identify new markets, introduce new products, validate existing market share, analyze competition and assess the potential for products to impact existing markets. With impressive academic credentials and broad and deep knowledge of global industrial markets, our independent analysts and consultants develop the facts, figures, analysis and assessments to inform the decisions that will move your company ahead. Confidential inquiries to: custom@bccresearch.com or 781/205-2429.

DISCLAIMER

The information developed in this report is intended to be as reliable as possible at the time of publication and is of a professional nature. This information does not constitute managerial, legal or accounting advice, nor should it be considered as a corporate policy guide, laboratory manual or an endorsement of any product, as much of the information is speculative in nature. BCC Research and the author assume no responsibility for any loss or damage that might result from reliance on the reported information or from its use.

ISBN: 978-1-62296-582-3
December 2017